Solifenacin
- Generic Name
- Solifenacin
- Brand Names
- Vesicare
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N2O2
- CAS Number
- 242478-37-1
- Unique Ingredient Identifier
- A8910SQJ1U
- Background
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
- Indication
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms
- Conditions
- Ureteral Stent-Related Symptom
- Interventions
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Bir Hospital
- Target Recruit Count
- 189
- Registration Number
- NCT06803030
- Locations
- 🇳🇵
NAMS, Bir Hospital, Kathmandu, Bagmati, Nepal
Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)
- Conditions
- Urinary Incontinence in Children
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 236
- Registration Number
- NCT06551246
- Locations
- 🇩🇰
Department of Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus, Aarhus N, Denmark
🇩🇰Department of Pediatric and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Pediatric and Adolescent medicine, Esbjerg Hospital, Esbjerg, Denmark
Efficacy and Safety of VDS+SU in the Treatment of OAB-dry in Children
- Conditions
- Overactive BladderPediatric Disorder
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Xing Liu
- Target Recruit Count
- 180
- Registration Number
- NCT06489951
- Locations
- 🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder
- Conditions
- Urinary Bladder, OveractiveEffect of Drug
- Interventions
- Drug: Combined pharmacotherapy with Solifenacin and Mirabegron
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Mackay Memorial Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06479720
- Locations
- 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)
- Conditions
- Urinary Incontinence in Children
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 216
- Registration Number
- NCT06465576
- Locations
- 🇩🇰
Department of Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus, Aarhus N, Denmark
🇩🇰Department of Pediatric and Adolescent Medicine, Kolding Hospital, Kolding, Denmark
🇩🇰Department of Pediatric and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
- Conditions
- Urinary Bladder, OveractiveOveractive BladderUrinary Incontinence, Urge
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Xing Liu
- Target Recruit Count
- 150
- Registration Number
- NCT06201013
- Locations
- 🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity
- Conditions
- Urinary Bladder, OveractiveEffect of Drug
- Interventions
- Drug: Combination pharmacotherapy
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Mackay Memorial Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06197295
- Locations
- 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
Comparison of the Transcutaneous Tibial Nerve Stimulation and Drug Treatment' Effects in Women With Overactive Bladder
- Conditions
- Overactive Bladder SyndromeOveractive Bladder
- Interventions
- Device: Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Ege University
- Target Recruit Count
- 34
- Registration Number
- NCT06024005
- Locations
- 🇹🇷
Ege University, School of Medicine, Department of Obstetrics and Gynecology, İzmir, Turkey
IDB Injection Combined With PTNS for Managing Children With OAB Not Responding to Monotherapy
- Conditions
- Percutaneous Tibial Nerve StimulationBOTOX
- Interventions
- Procedure: Percutaneous tibial nerve stimulation groupDrug: Intradetrusor BOTOX groupCombination Product: Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Benha University
- Target Recruit Count
- 128
- Registration Number
- NCT05911594
- Locations
- 🇪🇬
Pediatric Urology departments Benha University Hospitals, Benha, Qalyubiyya, Egypt
Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- Device: electroacupuncture
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Shanghai University of Traditional Chinese Medicine
- Target Recruit Count
- 204
- Registration Number
- NCT05798403
- Locations
- 🇨🇳
Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.